← ANALYST RATINGS · TIPRANKS
Waters (WAT): analyst forecast and price target
Analyst consensus
Moderate Buy12 Buy5 Hold0 Sell
Ratings of 17 analysts in the last 3 months12-month forecast
Based on 17 price targets given in the last 3 months, the average target is $463, the highest $515, the lowest $400. The average is +6.0% from the last price of $437.
Analyst ratings 29
| Analyst | Firm | Price target | Rating | Upside | Action | Date | Move vs SPY | |
|---|---|---|---|---|---|---|---|---|
| AI xAi Medical - Diagnostics and ResearchxAI Grok-3 | TipRanks - xAI | $490 → $500+2.0% | Buy | +14.4% | Reiterated | 17.10.26on TipRanks Oct 16 23:05 | — | |
| AI DeepSeek Medical - Diagnostics and ResearchDeepSeek V3.2-Speciale | TipRanks - DeepSeek | $475 → $484+1.9% | Hold | +10.8% | Downgrade | 17.10.26on TipRanks Oct 16 23:05 | — | |
| AI OpenAI Medical - Diagnostics and ResearchOpenAI 5.2 | TipRanks - OpenAI | $460 → $469+2.0% | Hold | +7.3% | Reiterated | 17.10.26on TipRanks Oct 16 23:05 | — | |
| AI Anthropic Medical - Diagnostics and ResearchAnthropic Opus-4.5 | TipRanks - Anthropic | $451 → $460+2.0% | Hold | +5.3% | Reiterated | 17.10.26on TipRanks Oct 16 23:05 | — | |
| AI Google Medical - Diagnostics and ResearchGemini 3-pro | TipRanks - Google | $486 → $495+1.9% | Buy | +13.3% | Reiterated | 17.10.26on TipRanks Oct 16 23:05 | — | |
| AI PerPlexity Medical - Diagnostics and ResearchPerPlexity SonarPro | TipRanks - PerPlexity | $499 → $509+2.0% | Buy | +16.5% | Reiterated | 17.10.26on TipRanks Oct 16 23:05 | — | |
| Casey Woodring★★★★★★★★★★#2489 · hits 62% · avg +8.2% | J.P. Morgan | $400 → $435+8.7% | Hold | −0.4% | Reiterated | 16.10.26on TipRanks Oct 17 08:15 | −0.5% | ↗ |
| Eve Burstein★★★★★★★★★★#1300 · hits 72% · avg +25.0% | Bernstein | $450 | Buy | +3.0% | Reiterated | 16.10.26on TipRanks 06:45 | −0.5% | ↗ |
| Daniel Brennan★★★★★★★★★★#271 · hits 58% · avg +21.8% | TD Cowen | $475 → $515+8.4% | Buy | +17.9% | Reiterated | 13.10.26on TipRanks 08:41 | −0.7%next day +2.8% | ↗ |
| Eve Burstein★★★★★★★★★★#1300 · hits 72% · avg +25.0% | Bernstein | $450 | Buy | +3.0% | Reiterated | 12.10.26on TipRanks 06:30 | −0.3%next day −0.7% | ↗ |
| Michael Ryskin★★★★★★★★★★#1994 · hits 58% · avg +5.1% | Bank of America Securities | $430 → $465+8.1% | Hold | +6.4% | Reiterated | 09.10.26on TipRanks 08:10 | +0.5%next day −0.3% · 5 days +2.7% | ↗ |
| AI xAi Medical - Diagnostics and ResearchxAI Grok-3 | TipRanks - xAI | $495 → $490−1.0% | Buy | +12.1% | Reiterated | 09.10.26on TipRanks Oct 8 23:05 | — | |
| AI DeepSeek Medical - Diagnostics and ResearchDeepSeek V3.2-Speciale | TipRanks - DeepSeek | $480 → $475−1.0% | Hold | +8.7% | Downgrade | 09.10.26on TipRanks Oct 8 23:05 | — | |
| AI OpenAI Medical - Diagnostics and ResearchOpenAI 5.2 | TipRanks - OpenAI | $464 → $460−0.9% | Hold | +5.3% | Reiterated | 09.10.26on TipRanks Oct 8 23:05 | — | |
| AI Anthropic Medical - Diagnostics and ResearchAnthropic Opus-4.5 | TipRanks - Anthropic | $456 → $451−1.1% | Hold | +3.2% | Reiterated | 09.10.26on TipRanks Oct 8 23:05 | — | |
| AI Google Medical - Diagnostics and ResearchGemini 3-pro | TipRanks - Google | $491 → $486−1.0% | Buy | +11.2% | Reiterated | 09.10.26on TipRanks Oct 8 23:05 | — | |
| AI PerPlexity Medical - Diagnostics and ResearchPerPlexity SonarPro | TipRanks - PerPlexity | $504 → $499−1.0% | Buy | +14.2% | Reiterated | 09.10.26on TipRanks Oct 8 23:05 | — | |
| Luke Sergott★★★★★★★★★★#1255 · hits 49% · avg +9.8% | Barclays | $460 → $500+8.7% | Buy | +14.4% | Reiterated | 07.10.26on TipRanks 03:55 | +0.1%next day −1.2% · 5 days +1.1% | ↗ |
| AI xAi Medical - Diagnostics and ResearchxAI Grok-3 | TipRanks - xAI | $499 → $495−0.8% | Buy | +13.3% | Reiterated | 07.10.26on TipRanks Oct 6 23:05 | — | |
| AI DeepSeek Medical - Diagnostics and ResearchDeepSeek V3.2-Speciale | TipRanks - DeepSeek | $483 → $480−0.6% | Hold | +9.9% | Downgrade | 07.10.26on TipRanks Oct 6 23:05 | — | |
| AI OpenAI Medical - Diagnostics and ResearchOpenAI 5.2 | TipRanks - OpenAI | $468 → $464−0.9% | Hold | +6.2% | Reiterated | 07.10.26on TipRanks Oct 6 23:05 | — | |
| AI Anthropic Medical - Diagnostics and ResearchAnthropic Opus-4.5 | TipRanks - Anthropic | $459 → $456−0.7% | Hold | +4.4% | Reiterated | 07.10.26on TipRanks Oct 6 23:05 | — | |
| AI Google Medical - Diagnostics and ResearchGemini 3-pro | TipRanks - Google | $494 → $491−0.6% | Buy | +12.4% | Reiterated | 07.10.26on TipRanks Oct 6 23:05 | — | |
| AI PerPlexity Medical - Diagnostics and ResearchPerPlexity SonarPro | TipRanks - PerPlexity | $508 → $504−0.8% | Buy | +15.3% | Reiterated | 07.10.26on TipRanks Oct 6 23:05 | — | |
| Unknown Analyst | Jefferies | $455 | Buy | +4.1% | Reiterated | 01.10.26on TipRanks Oct 6 23:05 | −3.3%next day −0.8% · 5 days −0.5% | ↗ |
| Subbu Nambi★★★★★★★★★★#281 · hits 72% · avg +34.4% | Guggenheim | $440 → $490+11.4% | Buy | +12.1% | Reiterated | 01.10.26on TipRanks 08:35 | −3.3%next day −0.8% · 5 days −0.5% | ↗ |
| AI xAi Medical - Diagnostics and ResearchxAI Grok-3 | TipRanks - xAI | $412 → $499+21.1% | Buy | +14.2% | Reiterated | 01.10.26on TipRanks 00:05 | — | |
| AI DeepSeek Medical - Diagnostics and ResearchDeepSeek V3.2-Speciale | TipRanks - DeepSeek | $422 → $483+14.5% | Hold | +10.5% | Downgrade | 01.10.26on TipRanks 00:05 | — | |
| AI OpenAI Medical - Diagnostics and ResearchOpenAI 5.2 | TipRanks - OpenAI | $395 → $468+18.5% | Hold | +7.1% | Reiterated | 01.10.26on TipRanks 00:05 | — | |
| AI Anthropic Medical - Diagnostics and ResearchAnthropic Opus-4.5 | TipRanks - Anthropic | $386 → $459+18.9% | Hold | +5.0% | Reiterated | 01.10.26on TipRanks 00:05 | — | |
| AI Google Medical - Diagnostics and ResearchGemini 3-pro | TipRanks - Google | $420 → $494+17.6% | Buy | +13.1% | Reiterated | 01.10.26on TipRanks 00:05 | — | |
| AI PerPlexity Medical - Diagnostics and ResearchPerPlexity SonarPro | TipRanks - PerPlexity | $429 → $508+18.4% | Buy | +16.3% | Reiterated | 01.10.26on TipRanks 00:05 | — | |
| Eve Burstein★★★★★★★★★★#1300 · hits 72% · avg +25.0% | Bernstein | $450 | Buy | +3.0% | Reiterated | 25.09.26on TipRanks Sep 26 10:15 | +0.2%next day +2.9% · 5 days −1.7% | ↗ |
| Evie Koslosky★★★★★★★★★★#9740 · hits 58% · avg −3.1% | Goldman Sachs | $465 → $515+10.8% | Buy | +17.9% | Assigned | 20.09.26on TipRanks Sep 21 06:15 | −1.0%next day +0.4% · 5 days +5.5% | ↗ |
| Kallum Titchmarsh★★★★★★★★★★#2647 · hits 58% · avg +9.6% | Morgan Stanley | $430 | Hold | −1.6% | Reiterated | 14.09.26on TipRanks Sep 15 07:25 | +0.9%next day +2.2% · 5 days +1.5% | ↗ |
| Doug Schenkel★★★★★★★★★★#216 · hits 65% · avg +26.2% | Wolfe Research | $375 → $490+30.7% | Buy | +12.1% | Upgrade | 09.09.26on TipRanks 08:35 | +0.9%next day −0.2% · 5 days +4.5% | ↗ |
| David Westenberg★★★★★★★★★★#602 · hits 56% · avg +17.3% | Piper Sandler | $400 → $480+20.0% | Buy | +9.9% | Upgrade | 27.08.26on TipRanks 05:45 | +1.1%next day −1.3% · 5 days −2.1% | ↗ |
| Dan Leonard★★★★★★★★★★#656 · hits 62% · avg +14.1% | RBC Capital | $475 | Buy | +8.7% | Reiterated | 24.08.26on TipRanks 06:55 | +0.3%next day +0.6% · 5 days +0.5% | ↗ |
| Joanne Wuensch★★★★★★★★★★#3684 · hits 55% · avg +2.3% | Citi | $425 → $470+10.6% | Buy | +7.6% | Reiterated | 10.08.26on TipRanks 06:50 | +1.2%next day +1.1% · 5 days −0.9% | ↗ |
| Daniel Brennan★★★★★★★★★★#271 · hits 58% · avg +21.8% | TD Cowen | $475 | Buy | +8.7% | Upgrade | 07.08.26on TipRanks Aug 5 05:45 | +1.2%next day +0.1% · 5 days +3.7% | ↗ |
| Casey Woodring★★★★★★★★★★#2489 · hits 62% · avg +8.2% | J.P. Morgan | $370 → $400+8.1% | Hold | −8.5% | Reiterated | 06.08.26on TipRanks Aug 7 08:10 | +0.1%next day +1.2% · 5 days +2.2% | ↗ |
| Justin Bowers★★★★★★★★★★#8679 · hits 47% · avg 0.0% | Deutsche Bank | $380 → $400+5.3% | Hold | −8.5% | Assigned | 05.08.26on TipRanks 09:25 | +1.2%next day +0.1% · 5 days +3.7% | ↗ |
| Vijay Kumar★★★★★★★★★★#2375 · hits 54% · avg +4.8% | Evercore ISI | $410 → $420+2.4% | Buy | −3.9% | Reiterated | 05.08.26on TipRanks 08:20 | +1.2%next day +0.1% · 5 days +3.7% | ↗ |
| Daniel Arias★★★★★★★★★★#1848 · hits 50% · avg +8.0% | Stifel Nicolaus | $380 → $420+10.5% | Hold | −3.9% | Assigned | 05.08.26on TipRanks 07:20 | +1.2%next day +0.1% · 5 days +3.7% | ↗ |
| Luke Sergott★★★★★★★★★★#1255 · hits 49% · avg +9.8% | Barclays | $425 → $460+8.2% | Buy | +5.3% | Reiterated | 05.08.26on TipRanks 04:13 | +1.2%next day +0.1% · 5 days +3.7% | ↗ |
| Subbu Nambi★★★★★★★★★★#281 · hits 72% · avg +34.4% | Guggenheim | $440 | Buy | +0.7% | Reiterated | 04.08.26on TipRanks Aug 5 08:00 | +3.9%next day +1.2% · 5 days +4.9% | ↗ |
| AI xAi Medical - Diagnostics and ResearchxAI Grok-3 | TipRanks - xAI | $423 → $422−0.2% | Buy | −3.4% | Reiterated | 04.08.26on TipRanks 20:05 | — | |
| AI Anthropic Medical - Diagnostics and ResearchAnthropic Opus-4.5 | TipRanks - Anthropic | $387 → $388+0.3% | Hold | −11.2% | Reiterated | 04.08.26on TipRanks 20:05 | — | |
| AI Google Medical - Diagnostics and ResearchGemini 3-pro | TipRanks - Google | $415 → $420+1.2% | Buy | −3.9% | Reiterated | 04.08.26on TipRanks 10:08 | — | |
| AI DeepSeek Medical - Diagnostics and ResearchDeepSeek V3.2-Speciale | TipRanks - DeepSeek | $411 → $422+2.7% | Buy | −3.4% | Upgrade | 04.08.26on TipRanks 10:08 | — | |
| AI OpenAI Medical - Diagnostics and ResearchOpenAI 5.2 | TipRanks - OpenAI | $413 → $395−4.4% | Hold | −9.6% | Reiterated | 04.08.26on TipRanks 10:08 | — | |
| AI PerPlexity Medical - Diagnostics and ResearchPerPlexity SonarPro | TipRanks - PerPlexity | $421 → $429+1.9% | Buy | −1.8% | Reiterated | 04.08.26on TipRanks 10:08 | — | |
| Matt Larew★★★★★★★★★★#816 · hits 63% · avg +19.3% | William Blair | — | Buy | — | Reiterated | 04.08.26on TipRanks 09:18 | +3.9%next day +1.2% · 5 days +4.9% | ↗ |
| Michael Ryskin★★★★★★★★★★#1994 · hits 58% · avg +5.1% | Bank of America Securities | $400 → $415+3.8% | Hold | −5.0% | Reiterated | 04.08.26on TipRanks 08:46 | +3.9%next day +1.2% · 5 days +4.9% | ↗ |
| Sidharth Sahoo★★★★★★★★★★#9090 · hits 43% · avg −0.9% | HSBC | $415 → $435+4.8% | Buy | −0.4% | Reiterated | 03.06.26on TipRanks 05:35 | +2.8%next day −1.2% · 5 days −0.5% | ↗ |
| Michael Polark★★★★★★★★★★#2909 · hits 51% · avg +6.5% | Wolfe Research | $425 | Buy | −2.7% | Reiterated | 01.06.26on TipRanks 16:55 | −1.8%next day +2.8% · 5 days +2.8% | ↗ |
| Brandon Couillard★★★★★★★★★★#287 · hits 63% · avg +18.4% | Wells Fargo | $355 → $370+4.2% | Hold | −15.3% | Reiterated | 14.05.26on TipRanks 07:20 | −1.3%next day 0.0% · 5 days +3.1% | ↗ |
| Catherine Ramsey Schulte★★★★★★★★★★#864 · hits 53% · avg +11.2% | Robert W. Baird | $362 → $387+6.9% | Buy | −11.4% | Reiterated | 06.05.26on TipRanks 07:06 | +0.6%next day +0.6% · 5 days −5.3% | ↗ |
| Tycho Peterson★★★★★★★★★★#1097 · hits 57% · avg +9.8% | Jefferies | $470 | Buy | +7.6% | Reiterated | 10.02.26on TipRanks 09:05 | −0.1%next day +0.7% · 5 days +1.0% | ↗ |
| No ratings for this filter. | ||||||||
Every rating the collector has kept for the last 12 months, including the earlier ones of the same analyst. Latest of each analyst
Best analysts covering Waters
TipRanks picks them by their record on this stock; the figures under the name are their record across all their ratings.
Most accurate
Most profitable
How the average price target moved
The average target of all analysts (their ratings of the 3 months before) on each day, the top analysts’ dashed, against the price; the site keeps this record since 1 October 2026. On 01.10.26: target $453 at a price of $439 (+3.0%); now: $463 at $437 (+6.0%).
PriceAverage targetTop analysts’ target
Recommendation trend
Strong BuyBuyHoldSell
| Rating | 05.26 | 06.26 | 07.26 | 08.26 | 09.26 | 10.26 |
|---|---|---|---|---|---|---|
| Strong Buy | 0 | 0 | 0 | 0 | 0 | 0 |
| Buy | 11 | 15 | 15 | 18 | 18 | 20 |
| Hold | 11 | 12 | 14 | 12 | 12 | 11 |
| Sell | 0 | 0 | 0 | 0 | 0 | 0 |
Earnings and sales forecast
Next report: 03.11.26 (Q3 2026, date not confirmed)
Earnings per share
Next quarter’s EPS estimate — $4.00 (from $3.92 to $4.03). Last quarter: $3.05.
Sales
Next quarter’s sales estimate — $1.8B (from $1.7B to $1.8B). Last quarter: $1.6B.
Best top-analyst consensus in the sector · Healthcare
About Waters
- CEO: Udit Batra
- Employees: 7,900
- 34 Maple Street, Milford, MA, 01757, US
- www.waters.com
Waters Corporation is a global leader in specialized measurement, delivering analytical solutions across Asia, the Americas, and Europe. The company operates through two main divisions: Waters and TA. Under its Waters segment, it engineers, manufactures, sells, and provides support for high and ultra-performance liquid chromatography and mass spectrometry (MS) systems. This includes essential consumables like chromatography columns and comprehensive post-warranty service plans. The TA segment focuses on designing, producing, selling, and servicing instruments for thermal analysis, rheometry, and calorimetry. Additionally, Waters develops and supplies sophisticated software that integrates with both its own instruments and those from other manufacturers. The company's advanced MS technology plays a crucial role in various applications, such as drug discovery and development (including clinical trial assessments), analyzing proteins involved in disease processes, ensuring nutritional safety, and conducting environmental testing. Its thermal analysis, rheometry, and calorimetry instruments are vital for assessing the suitability and stability of a wide range of materials, including fine chemicals, pharmaceuticals, water, polymers, metals, and viscous liquids. These instruments support diverse sectors like industrial manufacturing, consumer goods, healthcare products, and life science research. Waters' extensive client base spans the life sciences, pharmaceutical, biochemical, industrial, nutritional safety, environmental, academic, and governmental sectors, where its products are instrumental in research and development, quality assurance, and general laboratory operations. Established in 1958, Waters Corporation is headquartered in Milford, Massachusetts.
Data from the stock’s TipRanks forecast page, read 1 min ago. It is read again as soon as a new rating appears and at least every 8 hours. TipRanks ↗